Endocyte, Inc.

Endocyte, Inc.

Endocyte, Inc. company was founded in 1996 and is based in West Lafayette, Indiana. Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers.

Contact Details

Office Address

Endocyte, Inc.
3000 Kent Avenue, Suite A1-100
West Lafayette, IN, USA 47906
Phone: (765) 463-7175
Fax: (765) 463-9271

Executives

Chairman

John G. Clawson

President and CEO

P. Ron Ellis

Business Reviews for Endocyte, Inc.

Related Companies